Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas.


Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
02 2021
Historique:
received: 22 09 2020
revised: 06 12 2020
accepted: 13 12 2020
pubmed: 2 2 2021
medline: 30 10 2021
entrez: 1 2 2021
Statut: ppublish

Résumé

While the anti-PDGFRA antibody olaratumab failed to confirm an impact on survival in unselected advanced soft tissue sarcoma (STS) patients, the level of expression and the prognosis of platelet-derived growth factor (PDGF) receptors and ligands in STS remain unclear. We analyzed PDGF ligands and receptors' expression levels in a series of 255 patients with different histologies of STS [gastrointestinal stromal tumor (GIST), myxoid liposarcoma (MLPS), sarcoma with complex genomics, synovial sarcoma (SyS)] with Agilent single-color micro-arrays. We explored expression levels as prognostic values in univariate and multivariate analysis using R software (version 3.4.2). Complex patterns of correlation of expression between ligands and receptors were observed for each histotype. PDGFA levels were highest in SyS and lowest in MLPS (P < 4 × 10 The expression of PDGF ligands and receptors varies across sarcoma histological subtypes. PDGFA and D expression levels independently and inversely correlate with the risk of metastatic relapse.

Sections du résumé

BACKGROUND
While the anti-PDGFRA antibody olaratumab failed to confirm an impact on survival in unselected advanced soft tissue sarcoma (STS) patients, the level of expression and the prognosis of platelet-derived growth factor (PDGF) receptors and ligands in STS remain unclear.
PATIENTS AND METHODS
We analyzed PDGF ligands and receptors' expression levels in a series of 255 patients with different histologies of STS [gastrointestinal stromal tumor (GIST), myxoid liposarcoma (MLPS), sarcoma with complex genomics, synovial sarcoma (SyS)] with Agilent single-color micro-arrays. We explored expression levels as prognostic values in univariate and multivariate analysis using R software (version 3.4.2).
RESULTS
Complex patterns of correlation of expression between ligands and receptors were observed for each histotype. PDGFA levels were highest in SyS and lowest in MLPS (P < 4 × 10
CONCLUSIONS
The expression of PDGF ligands and receptors varies across sarcoma histological subtypes. PDGFA and D expression levels independently and inversely correlate with the risk of metastatic relapse.

Identifiants

pubmed: 33524869
pii: S2059-7029(20)32903-3
doi: 10.1016/j.esmoop.2020.100037
pmc: PMC7848659
pii:
doi:

Substances chimiques

Ligands 0
Lymphokines 0
PDGFD protein, human 0
Platelet-Derived Growth Factor 0
Proto-Oncogene Proteins c-sis 0
platelet-derived growth factor A 0
Receptor, Platelet-Derived Growth Factor beta EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100037

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure J-YB declares research support and honoraria from Lilly, & Bayer; other authors declare no potential conflicts of interest.

Auteurs

M Brahmi (M)

Centre Léon Bérard, Lyon, France. Electronic address: mehdi.brahmi@lyon.unicancer.fr.

T Lesluyes (T)

University of Bordeaux, Bordeaux, France; Inserm U1218, Institut Bergonié, Bordeaux, France; Inserm UMR1037, Cancer Research Center of Toulouse, Toulouse, France; Institut Claudius Regaud, Toulouse, France.

A Dufresne (A)

Centre Léon Bérard, Lyon, France.

M Toulmonde (M)

Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

A Italiano (A)

Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

O Mir (O)

Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

A Le Cesne (A)

Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

T Valentin (T)

Institut Claudius Regaud, Toulouse, France.

C Chevreau (C)

Institut Claudius Regaud, Toulouse, France.

S Bonvalot (S)

Department of Medical Oncology, Institut Curie, Paris, France.

N Penel (N)

Department of Medical Oncology, Centre Oscar Lambret, Lille, France.

J-M Coindre (JM)

University of Bordeaux, Bordeaux, France.

S Le Guellec (S)

Institut Claudius Regaud, Toulouse, France.

F Le Loarer (F)

Inserm U1218, Institut Bergonié, Bordeaux, France.

M Karanian (M)

Centre Léon Bérard, Lyon, France.

J-Y Blay (JY)

Centre Léon Bérard, Lyon, France; Université Claude Bernard, Lyon, France.

F Chibon (F)

Inserm UMR1037, Cancer Research Center of Toulouse, Toulouse, France; Institut Claudius Regaud, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH